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Abstract: Chronic kidney disease (CKD) and its associated morbidity pose a worldwide health 
problem. As well as risk of endstage renal disease requiring renal replacement therapy, cardio-
vascular disease is the leading cause of premature death among the CKD population. Proteinuria 
is a marker of renal injury that can often be detected earlier than any tangible decline in glom-
erular filtration rate. As well as being a risk marker for decline in renal function, proteinuria is 
now widely accepted as an independent risk factor for cardiovascular morbidity and mortality. 
This review will address the prognostic implications of proteinuria in the general population 
as well as other specific disease states including diabetes, hypertension and heart failure. 
A variety of pathophysiological mechanisms that may underlie the relationship between renal 
and cardiovascular disease have been proposed, including insulin resistance, inflammation, and 
endothelial dysfunction. As proteinuria has evolved into a therapeutic target for cardiovascular 
risk reduction in the clinical setting we will also review therapeutic strategies that should be 
considered for patients with persistent proteinuria.
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Introduction
The association between chronic kidney disease (CKD) and cardiovascular disease has 
long been recognised and current guidelines recommend that patients with CKD be 
considered to be at particularly high cardiovascular risk.1 Although often transient and 
benign, the persistent presence of protein or albumin in the urine has marked clinical 
significance as an early indicator of underlying renal pathology, preceding tangible 
decline in renal filtration function. In addition to its role as a marker for CKD risk, it 
is now widely accepted that proteinuria is an independent predictor of cardiovascular 
morbidity and mortality across divergent populations.2 This review will address the role 
of proteinuria as a cardiovascular risk marker, the mechanisms and risk factors proposed 
to underlie this relationship and current pharmacological and non-pharmacological 
treatment strategies for individuals with proteinuria. Due to heterogeneity of detection 
methods used in published studies, this article will consider classifications including 
microalbuminuria, albuminuria, and proteinuria.
Background
National Health and Nutrition Examination Survey study (NHANES) data demonstrated 
that proteinuria is present in 4% of men and 2% of women between 45 and 74 years 
of age in the general population3 and up to 26% of patients with estimated glomerular 
filtration rate (eGFR) ,30 mL/minute/1.73 m.2,4 Data from the Framingham Heart Study 
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found a higher prevalence among older people, with dipstick 
proteinuria detected in 17.4% of men and 12.9% of women 
at baseline.5 In treated hypertensive patients, the reported 
prevalence of proteinuria varies between 4 and 15%.6,7
Classifications of proteinuria according to the diagnostic 
test used are defined in Table 1. Although the accepted gold 
standard for measuring proteinuria is 24 hour urinary protein 
excretion, this method can be cumbersome for patients and 
frequent error is encountered due to improper collection. 
A spot urine dipstick sample is often considered to be a 
more practical alternative. This method has high specificity 
of 97% or greater but poor sensitivity as false negatives can 
be encountered when urine samples are particularly dilute.8 
The Kidney Disease Outcomes Quality Initiative (KDOQI) 
guidelines recommend initial screening of at risk individu-
als with a standard urine dipstick. Those with a positive test 
should then proceed to a confirmatory quantitative test such 
as spot urine protein:creatinine (PCR) or albumin:creatinine 
ratio (ACR), both of which have been shown to correlate well 
with 24 hour urine protein quantification.9 Spot urine tests 
are subject to a significant degree of variability depending 
on multiple individual factors, and therefore repeating these 
tests is essential to obtain confirmation of initial abnormal 
results.9
CKD and cardiovascular risk
The presence of CKD is a powerful predictor of adverse 
clinical outcomes.10,11 Cardiovascular disease is by far the 
most common cause of death in dialysis-dependent and 
renal transplant patients. Only a small minority of the 
CKD population progress to endstage renal disease requir-
ing renal replacement therapy (RRT), with death prior to 
RRT being far more common.11 A 2010 meta-analysis with 
data for over 1 million subjects reported that stage 3 CKD 
(eGFR ,60 mL/minute/1.73 m2) was associated with both 
cardiovascular and all-cause mortality.12 In a systematic 
review of associations between non-dialysis-dependent CKD 
and mortality, Tonelli et al reported that the absolute risk of 
death increased exponentially with declining renal function.13 
Even the earliest, clinically silent stages of CKD have been 
associated with major cardiovascular disease.14 In addition to 
reduced eGFR, ACR and dipstick positive proteinuria have 
also been associated with graded cardiovascular and all-cause 
mortality, acting as risk multipliers across all levels of renal 
function.15,16 In a large Canadian study, Hemmelgarn et al 
found that heavy proteinuria independently increased risk of 
death, myocardial infarction (MI) and progression of CKD 
in particular patient groups.17
Proteinuria and clinical  
cardiovascular outcomes
General population
Evidence now suggests that proteinuria has implications 
for all-cause mortality and cardiovascular outcomes at a 
general population level, not only in individuals with CKD. 
Population based cohort studies have shown that multi-
variable relative risks of cardiovascular disease mortality 
for proteinuria range from 1.2–2.9.3,18,19 The Prevention of 
Renal and Vascular Endstage Disease (PREVEND) study 
included over 40,000 individuals and found that a 2-fold 
increase in ACR equated to close to a 30% increase in risk 
for cardiovascular mortality.20 Moreover, this relationship 
is constant across distinct ethnic groups1,21–23 and in elderly 
populations.5,24 In terms of cardiovascular morbidity, dipstick 
positive proteinuria and ACR have emerged as predictors of 
cardiovascular diseases including ischemic heart disease, 
stroke, and hypertension in the general population, with 
some sources suggesting that proteinuria is a stronger pre-
dictor of outcome than traditional risk factors such as blood 
pressure and cholesterol.7,22,25,26 Indeed, the Heart Outcomes 
Prevention Evaluation (HOPE) study found that  proteinuria 
was associated with adverse outcome independently of 
Table 1 Classification of proteinuria
Diagnostic test Normal albuminuria Microalbuminuria Albuminuria Proteinuria
24 hour urine albumin  
collection
,30 mg/24 hours 30–300 mg/24 hours .300 mg/24 hours .300 mg/ 
24 hours
Spot urine dipstick ,30 mg/dL N/A .30 mg/dL .30 mg/dL
Spot urine albumin  
to creatinine ratio
,17 mg/g (men) 
,25 mg/g (women) 
,2.5 mg/mmol (men) 
,3.5 mg/mmol (women) 
,30 ug/mg
17–250 mg/g (men) 
25–355 mg/g (women) 
,35 mg/mmol 
30–300 ug/mg
.250 mg/g (men) 
.355 mg/g (women) 
.35 mg/mmol 
.300 ug/mg
N/A
Spot urine protein  
to creatinine ratio
,200 mg/g 
,45 mg/mmol
N/A N/A .200 mg/g 
.45 mg/mmol
Abbreviation:  N/A, not available.
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traditional cardiovascular risk factors.27 Furthermore, 
cardiovascular risk appears to be increased even at levels 
of urinary protein excretion that are not considered to be 
pathological28 and in fact there is no distinct threshold level 
that confers increased cardiovascular risk; rather, increasing 
albuminuria is associated with a graded increase in risk.29,30 
Proteinuria has also been associated with increased risk of 
atherosclerotic events affecting the peripheral vasculature. 
Patients with proteinuria have been shown to have increased 
risk of incident stroke. A 2010 meta-analysis of studies 
totaling 48,000 participants reported that the presence of 
microalbuminuria was associated with a future stroke risk 
90% greater than that of normoalbuminuric individuals. The 
impact of microalbuminuria was greatest on ischemic stroke 
incidence in those with a prior history of cerebrovascular 
disease and found to be relatively modest within the diabetic 
population.31 A further meta-analysis of the relationship 
between proteinuria and stroke has suggested that risk rises 
with degree of urinary protein excretion.32
Hypertension and ischemic heart disease
In the hypertensive population, studies suggest that microal-
buminuria confers a 4 times greater risk of subsequent isch-
emic heart disease than in normoalbuminuric individuals.33 
This effect appears to be independent of conventional ath-
erosclerotic risk factors. In addition, albuminuria has been 
associated with the presence of left ventricular hypertrophy 
in patients with hypertension and diabetes.29,34–36 It has also 
been demonstrated that in individuals with stable underlying 
coronary artery disease, proteinuria confers increased risks 
of all-cause and cardiovascular mortality, even at lower lev-
els within the defined “normal range”.37 This has also been 
shown in individuals who have recently suffered a coronary 
event.38,39 The Pravastatin or Atorvastatin Evaluation and 
Infection Therapy-Thrombolysis in Myocardial Infarction 
(PROVE IT-TIMI 22) study showed that macro- rather 
than microalbuminuria was a better predictor of mortality 
in this group.39
Diabetes
Since the mid-1980s, accumulating evidence has linked 
microalbuminuria with mortality in patients with  diabetes,40–42 
both those with reduced and normal eGFR.43,44 Data from 
a pooled analysis of cohort studies including more than 
2,000 patients suggest that the overall odds ratio for all-cause 
mortality in type 2 diabetic patients with microalbuminuria 
is 2.4 (confidence interval [CI] 1.8–3.1).45 Similarly, data 
suggest that type 1 diabetic patients with albuminuria have 
nine times greater cardiovascular mortality than those who 
are normoalbuminuric.46 The strong association between 
proteinuria and cardiovascular morbidity and mortality 
in type 2 diabetes has also been well-documented, both 
in patients with and without nephropathy.47–49 Data from the 
World Health Organization (WHO) Multinational Study 
of Vascular  Disease in Diabetics confirm the association 
between clinical proteinuria and ischemic heart disease 
in type 2 diabetes.50 However, the Bypass Angioplasty 
 Revascularization  Investigation 2  Diabetes study of type 
2 diabetic patients with cardiovascular disease reported that 
only 33% of participants had clinically confirmed albu-
minuria, although this was found to be associated with left 
ventricular dysfunction and peripheral vascular disease.51 
The Strong Heart Study confirmed association between 
albuminuria and abnormal systolic and diastolic ventricular 
function in individuals with type 2 diabetes.52 These findings 
have been replicated in the Non-Insulin-Dependent Diabetes, 
Hypertension, Microalbuminuria or Proteinuria, Cardiovas-
cular Events, and Ramipril (DIABHYCAR), Reduction of 
Endpoints in NIDDM with the Angiotensin II Antagonist 
Losartan (RENAAL) and Losartan Intervention for Endpoint 
Reduction (LIFE) studies.53–55
Heart failure
Chronic heart failure lies at the end of the spectrum of 
cardiovascular disease, with 32% of individuals admitted to 
hospital with a diagnosis of heart failure dying within 1-year. 
It is thought to affect around 14 million people in Europe 
and 4.8 million Americans.56 A 2005 study of 94 stable 
chronic heart failure patients with New York Heart Associa-
tion (NYHA) functional class III to IV symptoms found that 
32% had evidence of microalbuminuria.57 Similar findings 
have been published from follow up of 2,310 patients in the 
 Candesartan in Heart Failure-Assessment of Reduction in 
Mortality and Morbidity (CHARM) study, with 30% of 
patients having microalbuminuria and a further 11% with 
confirmed macroalbuminuria58 and these were echoed in the 
Aliskiren Observation of Heart Failure Treatment (ALOFT) 
study.59 Proteinuria is a well documented risk factor for 
heart failure57 but, in addition, appears to provide prognos-
tic information. In the CHARM population, ACR was an 
independent predictor of mortality, conferring a 40%–80% 
increase in relative risk. It also predicted outcome when 
assessed as a continuous variable with each 100 mg/mmol 
increment conferring a 10% increase in mortality risk. 
The Prospective Randomized Enalapril Study Evaluating 
Regression of Ventricular Enlargement (PRESERVE) study 
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found that dipstick positive proteinuria was an independent 
predictor of clinical outcome in heart failure patients irrespec-
tive of specific level of proteinuria.60 Microalbuminuria also 
conferred a 30%–70% increased risk of hospitalization for 
heart failure.58 Data from the ALOFT study suggested that 
albuminuria predicted greater left ventricular end diastolic 
dimension and a trend towards increased N-terminal prohor-
mone of brain natriuretic peptide (NT-pro BNP) levels.59
Surrogate cardiovascular risk markers
A number of studies have demonstrated an independent 
association between proteinuria and other surrogate mark-
ers of cardiovascular disease. For example, data from the 
PREVEND study found microalbuminuria to be indepen-
dently associated with electrocardiographic (ECG) indicators 
of myocardial ischemia.61 In addition, a number of cross 
sectional studies have linked microalbuminuria with carotid 
artery intima media thickness.62,63 The association between 
microalbuminuria and left ventricular hypertrophy (LVH) 
has been shown in a number of cohorts including the LIFE 
and Multi-Ethnic Study of Atherosclerosis (MESA) popula-
tions, where albuminuria was linked with both electrocar-
diogram (ECG) and magnetic resonance imaging (MRI) 
defined LVH.30,64 Microalbuminuria was also associated 
with increased coronary artery calcification scores in the 
MESA trial,64 and with carotid-femoral pulse wave velocity 
in Framingham data.65
Mechanisms underlying cardiovascular  
consequences of proteinuria
The Steno hypothesis suggested that urinary protein excre-
tion not only reflects localized subclinical renal disease but 
also a more generalized vascular endothelial dysfunction.66 
High-sensitivity troponin T (hs-TnT) as a marker of vascu-
lar micronecrosis has been found to independently predict 
transitions in albuminuria grade.67 Microalbuminuria is also 
accompanied by a fall in adiponectin levels and elevated 
C-reactive protein (CRP)68 and there appears to be a sig-
nificant correlation between degree of proteinuria and CRP 
level.2 Evidence has also linked proteinuria with asymmetric 
dimethylarginine (ADMA), an inflammatory biomarker 
which causes endothelial dysfunction through inhibition 
of nitric oxide production.69 Circulating von Willebrand 
Factor (vWF) antigen is released in greater concentrations 
in response to endothelial cell damage. Levels of vWF have 
been shown to be higher in patients with microalbuminuria 
compared to control subject.70 Macrovascular endothelial 
dysfunction assessed by flow-mediated dilatation has been 
shown to be impaired in individuals with proteinuria.2 
 Vascular endothelial growth factor (VEGF) is another 
interesting potential mechanistic link between proteinuria 
and endothelial dysfunction. Use of VEGF-antagonists as 
angiogenesis inhibitors for the treatment of patients with 
cancers have been associated with increased incidence of 
proteinuria and hypertension, an effect which was reversed 
on withdrawal of therapy.71
As well as inflammation and endothelial dysfunction, 
thrombogenic factors have been implicated as potential 
mechanisms underlying the relationship between proteinu-
ria and cardiovascular disease. In addition to vWF, soluble 
vascular cell adhesion molecule, fibrinogen, and tissue plas-
minogen activator have been found to correlate with urinary 
albumin excretion.72 A variety of hemostatic abnormalities 
have been described in patients with diabetes73 and it has been 
suggested that high platelet adhesiveness and erythrocyte 
aggregation demonstrated in diabetic patients with protei-
nuria could indicate increased thrombosis risk.74
Both insulin resistance and proteinuria have been 
associated with atherogenesis. The Insulin Resistance 
Atherosclerosis Study involving 982 nondiabetic participants 
found that microalbuminuric subjects had lower insulin sen-
sitivity and higher plasma insulin levels compared to normal 
albuminuric participants, leading the authors to propose that 
insulin resistance has a role to play in the increased cardio-
vascular risk conferred by proteinuria.75 Hyperinsulinemia 
has been shown to cause renal vasodilatation and increased 
glomerular filtration rate in rats, with some suggesting that 
this localized elevated pressure is involved in regulating 
urinary albumin excretion.75 As well as demonstrating asso-
ciation between insulin resistance and microalbuminuria, 
Bianchi et al noted that in patients with essential hyperten-
sion, microalbuminuria was associated with altered lipid 
profile and an abnormal circadian blood pressure pattern, 
thus forming part of a cluster with potential to modify car-
diovascular risk in these individuals.76
Risk factors for proteinuria
Despite its evolving role as a major risk factor for cardiovas-
cular disease, little is known about factors that determine the 
onset of proteinuria. The majority of studies demonstrating 
relationships between proteinuria and other major cardiovas-
cular risk factors are cross-sectional and so inference regard-
ing causality cannot be drawn. In one 10-year prospective 
cohort study of 157,377 healthy Korean adults who were free 
of proteinuria at baseline, fasting glucose and cholesterol 
levels, as well as body mass index and blood pressure were 
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found to be independent predictors of incident proteinuria. 
Furthermore, cardiovascular risk increased in a progressive, 
dose-response manner, even at levels of protein excretion 
falling below currently accepted thresholds for cardiovascular 
disease prevention.77 Data from the Baltimore Longitudinal 
Study of Ageing confirmed the association between albu-
minuria and blood pressure, but suggested that urine albumin 
excretion was more strongly associated with systolic blood 
pressure and pulse pressure, and this finding was statistically 
significant only in males.78 Certainly, links between abnormal 
lipid profiles and CKD are well documented in both diabetic 
and non-diabetic populations.79,80 Obesity has been associ-
ated with glomerular hyperfiltration and microalbuminuria in 
subjects with and without diabetes.77,81 A number of studies 
have linked body mass index with incident proteinuria but 
it has been suggested that perhaps body fat distribution is 
more significant as central body fat appears to confer greater 
risk in lean, overweight and clinically obese patients.82 Risk 
of incident proteinuria appears to increase in parallel with 
the number of features of the metabolic syndrome elicited 
in individuals, regardless of age or sex.83
A cluster of cardiovascular risk factors has also been 
noted in hypertensive populations with microalbuminuria. 
In a study of normal albuminuric patients who were under 
50 years old with essential hypertension followed up over 
3 years, baseline microalbuminuria values and the slopes 
of systolic blood pressure and fasting glucose emerged as 
independent predictors of incident proteinuria.84 Evidence 
also links hyperinsulinemia with microalbuminuria, and 
the increase in baseline albumin excretion may reflect a 
degree of subclinical end-organ damage in values below the 
defined threshold for microalbuminuria. The Hypertension 
and Ambulatory Recording Venetia Study (HARVEST) 
study followed normal albuminuric hypertensive patients for 
7 years and confirmed that 24 hour systolic blood pressure 
was a predictor of microalbuminuria, but also named age and 
female sex amongst implicated risk factors.85
The interrelationship between proteinuria and diabetes 
is well-documented. In a cross sectional study evaluating 
24,000 type 2 diabetic patients, elevated albumin excre-
tion was most prevalent in Asian and Hispanic patients. 
HbA
1c
, blood pressure, diabetes duration, smoking, and 
baseline renal function were all independent risk factors 
for miroalbuminuria.86 Surprisingly, body mass index was 
not a risk factor for incident proteinuria, perhaps because 
microalbuminuria was most prevalent in the Asian popula-
tion, who had lower values. In cross-sectional data from the 
Randomized Olmesartan and Diabetes Microalbuminuria 
Prevention (ROADMAP) study, the factors most strongly 
correlated with degree of albuminuria within the normal 
range were blood pressure, pulse pressure, HbA
1c
, eGFR, 
and uric acid levels. In terms of categorical variables, higher 
albumin excretion was found in those with greater waist 
circumference, smokers, females and those who were treated 
with insulin.81 Although such observational correlations do 
not infer causality, many of the factors linked to albumin 
excretion are potential targets for intervention when aiming 
to minimize overall cardiovascular risk.
Pharmacological interventions
Given that the presence of proteinuria is independently associ-
ated with increased risk of cardiovascular morbidity and mor-
tality it has evolved into a therapeutic target for cardiovascular 
risk reduction. In the LIFE study, greater reductions in urinary 
albumin excretion were seen in subjects with the lowest cardio-
vascular event rate.87 Similar findings have been published from 
the RENAAL study49 but results of other projects such as the 
Prevention of Renal and Vascular Endstage Disease Interven-
tion Trial (PREVEND- IT) have been less convincing.88
Cardiovascular risk management in patients with 
proteinuria focuses on reduction or control of degree of 
proteinuria and modification of additional risk factors 
including blood pressure, diabetes, lipid profile, smoking, 
and obesity. Results of the Modification of Diet in Renal 
Disease study highlighted the importance of tight blood 
pressure control in patients with CKD and proteinuria89 as 
did the UK Prospective Diabetes Study (UKPDS) for those 
with diabetes.90 Current evidence-based guidelines highlight 
the importance of renin-angiotensin-aldosterone system 
(RAAS) inhibition (Figure 1) as the first line therapeutic 
strategy in terms of slowing progression of nephropathy and 
reducing proteinuria in these populations.91,92 Many patients 
will require additional antihypertensive therapy which should 
be prescribed according to each individual’s characteristics. 
These additional agents may not have specific antiproteinu-
ric properties but lowering of blood pressure itself can have 
beneficial effects on protein excretion.89,90
RAAS blocking agents
The renoprotective benefits of angiotensin-converting 
enzyme inhibitors (ACE-inhibitors) and angiotensin recep-
tor blockers in both diabetic and non-diabetic chronic kid-
ney disease are well documented and out of the scope of this 
review.93–97 In a sub-analysis of the HOPE study, ramipril 
treatment resulted in significantly reduced cardiovascular risk 
in participants with renal impairment. This cardioprotective 
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effect was attributed to proteinuria reduction and limiting 
the deleterious effects of angiotensin II.98 Similar reductions 
in cardiovascular endpoints were shown in the diabetic 
subset (micro-HOPE).95 In another study, captopril reduced 
mortality in type 1 diabetic patients with nephropathy.94 
Angiotensin receptor blockers have also been shown to 
improve cardiovascular morbidity and mortality. For 
example, in the LIFE study, losartan therapy reduced 
occurrence of the primary composite endpoint including 
death, myocardial infarction, and stroke in both diabetic 
and non-diabetic participants concomitant with reduction 
in albuminuria.99,100 In addition, the Irbesartan Diabetic 
Nephropathy Trial demonstrated concomitant reductions in 
urinary protein excretion and cardiovascular endpoints in 
hypertensive type 2 diabetic participants;101 however, in the 
RENAAL trial, losartan therapy reduced hospitalizations 
for heart failure but did not show any significant effect on 
mortality rate.97
early intervention/dual RAAS blockade
A number of studies have explored the risks and benefits 
of early initiation of RAAS blocking agents, or dual RAAS 
blockade. The ROADMAP study investigated early initia-
tion of angiotensin receptor blockade in normoalbuminuric 
patients with type 2 diabetes and showed that this did indeed 
delay onset of microalbuminuria. This did not, however, 
translate into a beneficial impact on cardiovascular risk.102 
The Ongoing Telmisartan Alone and in combination with 
Ramipril Global Endpoint Trial (ONTARGET) randomized 
participants with vascular disease or diabetes to receive 
telmisartan, ramipril, or a combination of both. Combination 
therapy was shown to offer greater reduction in proteinuria 
Angiotensinogen 
Angiotensin I 
Angiotensin II 
Angiotensin
receptor I  
Aldosterone Mineralocorticoid 
receptor 
Angiotensin 
receptor II  
Renin inhibitors  
ACE inhibitors Angiotensin receptor
antagonists
Mineralocorticoid 
receptor antagonists  
Figure 1 RAAS blocking agents and sites of action.
Abbreviations: ACe, angiotensin-converting-enzyme; RAAS, renin-angiotensin-aldosterone system.
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but this apparent benefit was offset by the lack of overall 
benefit in terms of cardiovascular outcomes and indeed a 
significant increase in adverse events, such as hypotensive 
symptoms and renal dysfunction.103,104 In adults with pro-
teinuric CKD, the addition of aldosterone antagonists such 
as spironolactone or eplerenone to angiotensin-converting-
enzyme (ACE)-inhibitor or angiotensin receptor blocker 
therapy has been shown to reduce protein excretion but to 
increase risk of adverse events such as hyperkalemia.105
Direct renin inhibitors
Direct renin inhibition offers potential to further optimize 
RAAS blockade by interfering with the first step in the pathway. 
Aliskiren is the first of this class to be licensed for treatment 
of hypertension. In comparative studies with other antihy-
pertensives, aliskiren monotherapy appears to provide blood 
pressure reductions similar to those achieved with losartan or 
lisinopril106,107 as well as significant additive blood pressure 
reduction in combination with other agents.108,109 Several trials 
have shown that treatment with direct renin inhibitors such as 
Aliskiren in combination with other RAAS blocking agents 
have beneficial effects on endpoints including proteinuria and 
left ventricular hypertrophy in patients with diabetic neph-
ropathy and non-diabetic CKD including transplant recipients 
or heart failure.110–113 The recent Aliskiren Trial in Type 2 
 Diabetes Using Cardiorenal Endpoints (ALTITUDE), however, 
was terminated early because of increased adverse outcomes 
including non-fatal stroke, hypotension, and hyperkalemia114 
and further prospective studies are needed to confirm the safety 
and tolerability of these agents in CKD populations.
endothelin A blockade
Although effective and the current mainstay of treatment of 
proteinuria, RAAS blockade does not always completely 
retard progression of proteinuria.115 Experimental data have 
demonstrated that endothelin A blockade can have favorable 
antiproteinuric and antifibrotic effects and these have been 
confirmed in studies in patients with diabetic nephropathy.116 
Encouraging results have been published from a short term 
pilot study of Atrasentan documenting significant reduction 
in proteinuria in participants with diabetic nephropathy 
although studies on long term safety and efficacy are lacking 
and some negative effects have been demonstrated in patients 
with underlying cardiac disease.117
Statins
As well as being effective cholesterol-lowering agents 
with positive effects on cardiovascular outcomes, some 
have suggested that statins have an antiproteinuric effect. 
In a 2006 meta-analysis, statins were shown to reduce 
albuminuria in 13 out of 15 studies reviewed. The degree 
of reduction appeared to be greater in individuals who had 
higher baseline albumin excretion although there was marked 
variability in study quality.118 A subsequent meta-analysis 
including randomized controlled trials of statins in patients 
with CKD again showed a significant reduction in protein 
excretion as well as a reduction in cardiovascular events.119 
It is unclear whether these perceived benefits are the result 
of lipid-lowering effects on endothelial function, reduction 
of inflammation and oxidative stress, or inhibitory effects on 
renal endothelin 1.120
Non-pharmacological interventions
As well as known carcinogenic effects, smoking has been 
shown to induce intimal proliferation and vascular hyaline 
thickening.121 As such, cigarette smoking is accepted as a 
major risk factor for cardiovascular disease. Similar histo-
logical changes have been described in the kidney.122 Multiple 
studies have shown an association between smoking and renal 
damage, at general population level as well as in patients 
with diabetes or hypertension.123 In epidemiological studies 
of otherwise healthy participants, the incidence of proteinuria 
has been positively associated with the number of cigarettes 
smoked per day, particularly in males124 and although no 
specific data exist to support cessation of smoking for reduc-
tion of proteinuria, smoking cessation is advised in KDOQI 
guidance on hypertension in CKD.
Obesity has been shown to be associated with 
proteinuria.125,126 Weight loss in combination with ACE-
inhibitor therapy have been shown to decrease levels of 
protein excretion in obese patients as well as proteinuria of 
other etiologies including diabetes.127 Moreover, a significant 
correlation between level of weight loss attained and reduc-
tion in proteinuria was demonstrated in the same study.127
Dietary protein restriction in patients with CKD remains 
a controversial issue due to the delicate balance between 
slowing progression of proteinuria and the importance of 
good nutritional status in chronic disease. Although limiting 
dietary protein intake to between 0.75 and 1.0 g/kg/day is 
often recommended in the later stages of CKD, these diets 
can be unpalatable and compliance is variable. In addition, 
 guidelines also recommend dietary sodium restriction to 
reduce cardiovascular risk in patients with CKD.9 Although no 
specific guidance exists on sodium restriction in patients with 
proteinuria, evidence suggests that dietary sodium restriction 
can enhance the effects of RAAS blocking agents in reducing 
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urinary protein excretion.128,129 Most clinical guidelines sug-
gest that a dietetic review for discussion of such modifications 
be considered for patients with advanced CKD although no 
specific guidance is available for the earlier stages of disease 
when GFR remains .60 mL/minute/1.73 m2.
Renal sympathetic innervation is another key component 
of the pathogenesis of hypertension through its effects on renin 
secretion, renal sodium absorption and glomerular filtration 
rate.130 In recent years, catheter-based renal sympathetic den-
ervation has gained much attention as a potential tool in the 
management of resistant hypertension. Preliminary evidence 
suggests that this procedure can offer significant blood pres-
sure reduction for resistant hypertensive patients with effects 
maintained at 24 months follow up,131,132 as well as beneficial 
effects on left ventricular mass and systolic function and arte-
rial stiffness as measured by pulse wave velocity.133 In terms 
of renal hemodynamics, recent evidence suggests that renal 
denervation improved ultrasound renal resistive indices. This 
study also demonstrated that renal function as measured by 
creatinine and cystatin C was unchanged at 6 months fol-
low up, suggesting that the procedure itself has no adverse 
effects on the kidneys at least in the short term. Urinary 
albumin excretion remained unchanged after denervation but 
the number of patients with micro or macroalbuminuria did 
fall, although it should be kept in mind that this was a small 
study.134 Whether this approach is equally safe and effective 
over longer term follow up in patients with eGFR less than 
45 mL/minute remains to be seen.
Conclusion
The significant burden on health services posed by cardio-
vascular disease has prompted investigation of prognostic 
markers and therapeutic targets. There is a clear association 
between proteinuria and cardiovascular outcomes despite 
marked heterogeneity in the literature when considering 
the method of detection used and classification of degree 
of proteinuria. This association has been demonstrated both 
in disease population including hypertensives, diabetic 
patients, and those with CKD, as well as in otherwise healthy 
individuals. Proteinuria has evolved into a surrogate marker 
of cardiovascular risk and it seems intuitive that earlier 
detection and more aggressive intervention may serve to 
reduce risk in affected individuals. Several publications have 
considered the cost-effectiveness of population screening. 
In 2003 Boulware et al concluded that population screening 
for dipstick proteinuria was not cost-effective in terms of 
CKD morbidity and mortality unless specifically targeted 
towards higher risk groups such as hypertensive or elderly 
patients and done at less frequent intervals.135 When con-
sidering prevention of cardiovascular events, an analysis 
of the PREVEND-IT study was more favourable.136 RAAS 
inhibition, together with control of additional cardiovascular 
risk factors, remains the mainstay of treatment for individu-
als with proteinuria. Studies of earlier and more aggressive 
intervention with two or more RAAS blocking agents have 
demonstrated reduction in proteinuria but this has not yet 
translated into reduction in hard clinical cardiovascular end-
points and these studies have also reported a greater degree 
of side effects and adverse events.
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